What Do You Need to Know About Novavax (NVAX) Before Investing?

Mid-cap Healthcare company Novavax has moved -0.7% so far today on a volume of 2,141,084, compared to its average of 6,332,166. In contrast, the S&P 500 index moved 1.4%.

Novavax trades -86.55% away from its average analyst target price of $77.67 per share. The 6 analysts following the stock have set target prices ranging from $13 to $207, and on average have given Novavax a rating of hold.

Anyone interested in buying NVAX should be aware of the facts below:

  • Novavax's current price is -80.4% below its Graham number of $53.3, which implies the stock has a margin of safety

  • Novavax has moved -94.3% over the last year, and the S&P 500 logged a change of -18.6%

  • Based on its trailing earning per share of -17.51, Novavax has a trailing 12 month Price to Earnings (P/E) ratio of -0.6 while the S&P 500 average is 15.97

  • NVAX has a forward P/E ratio of -2.0 based on its forward 12 month price to earnings (Eps) of $-5.31 per share

  • The company has a price to earnings growth (PEG) ratio of -0.03 — a number near or below 1 signifying that Novavax is fairly valued compared to its estimated growth potential

  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs.

  • Based in Gaithersburg, the company has 1,541 full time employees and a market cap of $888,113,280.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.